Revvity Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Revvity Inc trades at $155.03 (market cap $16.98B), while Virgin Galactic Holdings, Inc. trades at $2.87 (market cap $445.69M). The key difference: Revvity Inc is far larger — about 38.1× Virgin Galactic Holdings, Inc.'s market cap, and Revvity Inc pays a 0.18% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| RVTY | SPCE | |
|---|---|---|
Market Cap | $16.98B | $445.69M |
Volume | 1,456,900 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $157.36 | $7.52 |
52-Week Low | $82.26 | $2.17 |
Typical Hold Time | 12 Days | 69 Days |
Enterprise Value | $19.30B | $409.68M |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
SPCE trades at $2.875, down 4.49% on the day, reflecting ongoing volatility amid negative profitability and cash burn. The company continues to post significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have shown smaller-than-expected EPS losses. Technical indicators are bearish, with moving averages signaling selling pressure, while RSI levels suggest potential oversold conditions. Recent news highlights a delay in commercial Delta flights to 2027 but strong ticket demand and a legal settlement resolution.
The outlook remains high-risk due to persistent cash outflows and delayed revenue growth, yet long-term potential in space tourism offers speculative upside. Investment hinges on successful execution of the 2027 cash flow target and commercial flight timeline, but shareholder dilution and high short interest pose substantial risks. Analyst consensus is mixed, with 29% buy ratings reflecting cautious optimism amid fundamental challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →